← Back to Clinical Trials
Recruiting Phase 4 NCT02703220

Sleep Apnea in Elderly

Trial Parameters

Condition Sleep Apnea
Sponsor VA Office of Research and Development
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 100
Sex ALL
Min Age 60 Years
Max Age 89 Years
Start Date 2015-07-03
Completion 2026-07-31
Interventions
Hyperoxia/oxygenAcetazolamideFinasteride

Brief Summary

Sleep-disordered breathing (SDB or sleep apnea) is very common among elderly Veterans and leads to increased morbidity and mortality in this population. The proposal aims to identity whether oxygen, finasteride and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in the elderly via different mechanisms. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea in the elderly. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea. A cumulative effect of the investigators' research will fulfill the long-term goal of improving the quality of life of elderly Veterans suffering from sleep apnea and its potential life-threatening complications.

Eligibility Criteria

Inclusion Criteria: * Adults who are 60 years old and older, with mild to moderate sleep apnea with AHI \>/=5 to 20/hr with central, obstructive, mixed apneas and hypopneas. * For the finasteride protocol elderly men with above criteria will be enrolled. Exclusion Criteria: * Patients with severe sleep apnea (AHI\>20/hr) * Patients with history of prostate cancer * Males with hypogonadism * History of cardiac disease, including myocardial infarction * Bypass surgery * Atrial and ventricular tachy-bradycardias * Systolic congestive heart failure and Cheyne-Stokes respiration * Current unstable angina * Stroke * Schizophrenia * Untreated hypothyroidism * Seizure disorder * Preexisting renal failure and liver disorders * Failure to give informed consent. * Patients with significant pulmonary diseases by history and abnormal pulmonary function testing, including moderate obstructive/restrictive lung/chest wall disorders with resting oxygen saturation of \<96% or on supplemental oxygen * Pa

Related Trials